Congestive Heart Failure
Conditions
Keywords
Stem cells, Coronary Artery Bypass grafting, Congestive Heart Failure, Coronary Artery Disease, Angiogenesis
Brief summary
Study title: A Study of Combined Coronary Artery Bypass Grafting (CABG) and Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients with Congestive Heart Failure due to Ischemic Heart Disease (ACPs-CHF) Principle Investigator: Kit V. Arom ,M.D.,Ph.D. Deputy Director, Chief Cardio-Thoracic Surgeon, Bangkok Heart Hospital Study objective : To determine the safety and efficacy of injection of blood-borne autologous ACPs into the non-graftable area of the heart of patients with congestive heart failure due to ischemic heart disease Its main goal is evaluation of feasibility and safety of the combined technique. The efficacy of the treatment will be tested in the following trial. Study Design : Phase I , a single center, a non-randomized, open-label trial to test the safety, of intramyocardium transepicardium administration of ex vivo expanded autologous ACPs administered in combination with CABG operation in patients with congestive heart failure due to ischemic heart disease. The study is a preliminary training study, under the supervision of the experienced Dr. Patel the U.S. principal investigator. Study population : Total expected no. of patients : 5 main selection criteria : 1. Patients with or without signs of congestive heart failure due to ischemic heart disease who had maximal medical treatments. Not suitable to percutaneous intervention 2. All patients must have a recent coronary angiogram. Patients must be able to have OPCAB and then have Angiogenic Cell Precursors(ACPs) in non-graftable and/or infraction regions 3. Age 18 to 80 years 4. MRI demonstrating areas of viable and non-viable myocardium Investigational Product : The patients will be blood drawn 250 ml at D-8 for producting autologous ACPs (VescellTM), On D0 ,at least 1.5 million ACPs with viability \>75 % supended in 15 ml sterile cell culture medium will be injected 1 cm apart using a 23 gauge angled needle in 30 spots (0.5 ml /point) to the same patients by direct intramuscular approach at LV during CABG. The study consists of 4 periods: Screening ( D-14 to-9& D-8,Treatment(D0),Acute Safety follow-up (D1-2& D5-discharge),Chronic follow-up (D30 & D90)period ,total follow-up of each case is 3 months. Evaluation criteria : Safety : no.& duration of adverse event & serious adverse event Efficacy :NYHA, 6-minute walking test ,% LVEF by Echocardiography & C-MRI, % infracted scar area on C-MRI , Pro-BNP & 3 months of QoL(SF-36)
Detailed description
Five CAD patients who required CABG with or without congestive heart failure will undergo screening and receiving of ACPs 's injection by direct intramuscular during CABG operation. After that,the patients will come to follow up with investigator at 1 and 3 months post surgery in order to evaluate safety and efficacy of stem cells therapy(ACPs).
Interventions
PROCEDUREAngiogenic Cell Precursors(ACPs) or Vescell TM
at least 1.5 million of ACPs per one time of treatment
BIOLOGICALAngiogenic Cell Precusors
Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
Sponsors
TheraVitae Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with or without signs of congestive heart failure due to ischemic heart disease who had maximal medical treatments. Not suitable to percutaneous intervention 2. All patients must have a recent coronary angiogram. Patients must be able to have OPCAB and then have Angiogenic Cell Precursors(ACPs) in non-graftable and/or infraction regions 3. Age 18 to 80 years 4. Male or non-pregnant, non-lactating female 5. MRI demonstrating areas of viable and non-viable myocardium 6. Informed consent obtained and consent form signed
Exclusion criteria
1. Prior Cardiac Surgery or Heart Transplantation 2. Patient who received blood transfusions during the previous 4 weeks (to exclude the potential of non-autologous ACPs in the harvested blood). 3. Inability to communicate (that may interfere with the clinical evaluation of the patient) 4. Acute Myocardial infarction \< 6 days from acute event 5. Significant valvular disease or after valve replacement 6. Left Ventricular Aneurysm 7. Collagen tissue disease 8. History of Prior Radiation Exposure 9. History of alcohol or drug abuse within 3 months of screening 10. Renal failure (creatinine \> 2 mg/dl) or Hemodialysis 11. Hepatic failure or History of Liver Cirrhosis 12. Females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study. 13. Anemia (lower than 11mg/dl.hemoglobin for female and lower than 12 mg/dl for male) 14. Abnormal coagulation tests normal \[platelets, PT (INR), PTT\] 15. Stroke within the preceding 3 years 16. Malignancy within the preceding 3 years 17. Concurrent chronic or acute infectious disease 18. Severe concurrent medical disease (e.g., septicemia, HIV-1,2/HBV/HCV infections, insulin-dependent diabetes mellitus, systemic lupus erythematosus, multiple sclerosis, amyotrophic lateral sclerosis) 19. Chronic immunomodulating or cytotoxic drugs treatment 20. Patients who have rectal temp. above 38.40C for 2 consecutive days 21. Patient unlikely to be available for follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline to 3 months of QoL(SF-36) | 3 months |
| Evaluation criteria | 3 months |
| Safety : no.& duration of adverse event & serious adverse event | 3 months |
| Efficacy : EF , NYHA | 3 months |
| change from baseline to 1 & 3 months of NYHA, 6-minute walking test | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| change from baseline to 3 months of % LVEF by Echocardiography & C-MRI | 3 months |
| change from baseline to 3 months of % infracted scar area on C-MRI | 3 months |
| change from baseline to 3 months of QoL(SF-36) | 3 months |
| Efficacy:%EF,NYHA | 3 months |
Countries
Israel
Contacts
Primary ContactWannapa Kulwathanaporn, Master
Backup ContactDavid Czeiger, Ph.D.,M.D.
Outcome results
None listed